文献速递肺栓塞与肺血管病

甲基苯丙胺相关肺动脉高压的特征与结局

Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该前瞻性队列研究比较了2003至2015年斯坦福大学肺动脉高压项目中90例甲基苯丙胺相关肺动脉高压(Meth-APAH)与97例特发性肺动脉高压(iPAH)患者,发现Meth-APAH患者右房压更高、卒中体积指数更低,无事件生存率在2.5、5、10年分别为64.2%、47.2%、25%,临床恶化或死亡风险是iPAH的两倍以上(HR 2.04, 95%CI 1.28-3.25, P=0.003),加州住院(甲基)苯丙胺使用者PAH诊断风险增加2.6倍。

要点

  • Meth-APAH患者右房压更高、卒中体积指数更低,心衰症状更重。
  • Meth-APAH无事件生存率2.5年64.2%、5年47.2%、10年25%。
  • Meth-APAH临床恶化或死亡风险是iPAH的2.04倍(95%CI 1.28-3.25)。

核心结论

  • Meth-APAH是一种严重且进展性的PAH,结局较差。

研究设计与样本

  • 前瞻性队列研究,纳入2003至2015年斯坦福大学肺动脉高压项目的90例Meth-APAH和97例iPAH患者。
  • 利用加州住院患者数据估计(甲基)苯丙胺使用者中PAH的流行病学。

主要发现

  • Meth-APAH患者女性比例较低,但年龄、体重指数和6分钟步行距离与iPAH相似。
  • Meth-APAH患者右房压显著更高(12.7±6.8 vs 9.8±5.1 mm Hg;P=0.001),卒中体积指数更低(22.2±7.1 vs 25.5±8.7 ml/m2;P=0.01)。
  • Meth-APAH无事件生存率在2.5、5、10年分别为64.2%、47.2%、25%。
  • Meth-APAH临床恶化或死亡风险是iPAH的2.04倍(95%CI 1.28-3.25;P=0.003),独立于混杂因素。
  • 加州住院(甲基)苯丙胺使用者PAH诊断风险增加2.6倍。

临床怎么用

  • 对(甲基)苯丙胺使用者应警惕PAH,诊断时需评估药物暴露史。
  • Meth-APAH患者病情更重、预后更差,需密切监测和积极管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Although amphetamines are recognized as "likely" agents to cause drug- and toxin-associated pulmonary arterial hypertension (PAH), (meth)amphetamine-associated PAH (Meth-APAH) has not been well described. OBJECTIVES: To prospectively characterize the clinical presentation, histopathology, and outcomes of Meth-APAH compared with those of idiopathic PAH (iPAH). METHODS: We performed a prospective cohort study of patients with Meth-APAH and iPAH presenting to the Stanford University Pulmonary Hypertension Program between 2003 and 2015. Clinical, pulmonary angiography, histopathology, and outcomes data were compared. We used data from the Healthcare Cost and Utilization Project to estimate the epidemiology of PAH in (meth)amphetamine users hospitalized in California. MEASUREMENTS AND MAIN RESULTS: The study sample included 90 patients with Meth-APAH and 97 patients with iPAH. Patients with Meth-APAH were less likely to be female, but similar in age, body mass index, and 6-minute-walk distance to patients with iPAH. Patients with Meth-APAH reported more advanced heart failure symptoms, had significantly higher right atrial pressure (12.7 ± 6.8 vs. 9.8 ± 5.1 mm Hg; P = 0.001), and had lower stroke volume index (22.2 ± 7.1 vs. 25.5 ± 8.7 ml/m2; P = 0.01). Event-free survival in Meth-APAH was 64.2%, 47.2%, and 25% at 2.5, 5, and 10 years, respectively, representing more than double the risk of clinical worsening or death compared with iPAH (hazard ratio, 2.04; 95% confidence interval, 1.28-3.25; P = 0.003) independent of confounders. California data demonstrated a 2.6-fold increase in risk of PAH diagnosis in hospitalized (meth)amphetamine users. CONCLUSIONS: Meth-APAH is a severe and progressive form of PAH with poor outcomes. Future studies should focus on mechanisms of disease and potential therapeutic considerations.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Zamanian RT, Hedlin H, Greuenwald P, et al. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018. PMID: 28934596. doi:10.1164/rccm.201705-0943OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。